Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma.
10.1007/s11684-022-0956-8
- Author:
Yubing ZHOU
1
;
Xinyu HE
1
;
Yanan JIANG
1
;
Zitong WANG
1
;
Yin YU
1
;
Wenjie WU
1
;
Chenyang ZHANG
1
;
Jincheng LI
1
;
Yaping GUO
1
;
Xinhuan CHEN
1
;
Zhicai LIU
2
;
Jimin ZHAO
1
;
Kangdong LIU
3
;
Zigang DONG
4
Author Information
1. The Pathophysiology Department, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China.
2. Provincial Cooperative Innovation Center for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, 450000, China.
3. The Pathophysiology Department, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China. kdliu@zzu.edu.cn.
4. The Pathophysiology Department, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China. dongzg@zzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
benzydamine;
cyclin-dependent kinase 2;
esophageal squamous cell carcinoma;
patient-derived xenograft
- MeSH:
Humans;
Benzydamine;
Esophageal Neoplasms/drug therapy*;
Esophageal Squamous Cell Carcinoma/drug therapy*;
Molecular Docking Simulation;
Phosphorylation;
Cell Proliferation;
Cell Line, Tumor;
Apoptosis;
Cyclin-Dependent Kinase 2
- From:
Frontiers of Medicine
2023;17(2):290-303
- CountryChina
- Language:English
-
Abstract:
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.
